Klarup Dyreklinik ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
2024
2024/9
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  8.1% 6.3% 11.8% 6.4% 5.3%  
Credit score (0-100)  30 36 19 36 42  
Credit rating  BB BBB BB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
2024
2024/9

Net sales  0 0 0 0 0  
Gross profit  2,974 2,946 2,888 2,989 3,059  
EBITDA  1,648 1,311 431 1,017 1,049  
EBIT  924 654 -184 542 589  
Pre-tax profit (PTP)  874.4 645.0 -193.0 540.2 579.9  
Net earnings  666.6 503.1 -151.3 419.6 451.0  
Pre-tax profit without non-rec. items  874 645 -193 540 580  

 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
2024
2024/9

Tangible assets total  324 368 171 114 2,752  
Shareholders equity total  767 1,020 518 938 789  
Interest-bearing liabilities  648 24.4 217 0.0 1,542  
Balance sheet total (assets)  2,456 2,384 1,402 1,719 3,200  

Net Debt  625 -417 145 -597 1,515  
 
See the entire balance sheet

Volume 
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
2024
2024/9

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  2,974 2,946 2,888 2,989 3,059  
Gross profit growth  0.0% -1.0% -1.9% 3.5% 2.4%  
Employees  4 4 6 5 5  
Employee growth %  0.0% 0.0% 50.0% -16.7% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  2,456 2,384 1,402 1,719 3,200  
Balance sheet change%  0.0% -2.9% -41.2% 22.6% 86.2%  
Added value  1,648.5 1,311.0 431.3 1,157.2 1,049.5  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  1,238 -1,031 -1,231 -950 1,793  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  1.0 2.0 -1.0 1.0 2.0  

Profitability 
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
2024
2024/9
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  31.1% 22.2% -6.4% 18.1% 19.2%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  37.7% 27.0% -9.7% 35.1% 24.0%  
ROI %  65.4% 53.2% -20.6% 65.5% 36.2%  
ROE %  87.0% 56.3% -19.7% 57.6% 52.2%  

Solidity 
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
2024
2024/9
Equity ratio %  31.2% 42.8% 37.0% 54.6% 24.7%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  37.9% -31.8% 33.6% -58.7% 144.3%  
Gearing %  84.5% 2.4% 41.9% 0.0% 195.4%  
Net interest  0 0 0 0 0  
Financing costs %  15.6% 2.8% 7.8% 7.3% 1.4%  

Liquidity 
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
2024
2024/9
Quick Ratio  0.1 0.5 0.3 1.6 0.1  
Current Ratio  0.3 0.7 0.5 1.9 0.2  
Cash and cash equivalent  23.0 441.3 72.5 596.7 27.2  

Capital use efficiency 
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
2024
2024/9
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -955.0 -407.2 -471.9 561.4 -1,841.5  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
2024
2024/9
Net sales / employee  0 0 0 0 0  
Added value / employee  412 328 72 231 210  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  412 328 72 203 210  
EBIT / employee  231 163 -31 108 118  
Net earnings / employee  167 126 -25 84 90